Eicosapentaenoic acid vs. docosahexaenoic acid for the prevention of cardiovascular disease.
Current opinion in endocrinology, diabetes, and obesity（2023）
摘要
The totality of evidence suggests EPA alone, administered in a highly-purified, high-dose form, improves cardiovascular outcomes among patients with elevated triglycerides at high cardiovascular risk, but EPA and DHA together does not. Current guidelines endorse the use of IPE in statin-treated patients at high cardiovascular risk who have triglycerides >135 mg/dl.
更多查看译文
关键词
cardiovascular disease prevention,docosahexaenoic acid,eicosapentaenoic acid,icosapent ethyl,omega-3 fatty acids
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要